奥沙利铂加多西紫杉醇与奥沙利铂加长春瑞宾治疗43例老年晚期NSCLC的对照研究

A randomized trial comparing oxaliplatin plus docetaxel versus oxaliplatin Plus vinorelbine for the treatmen for elder patients with advanced non-small cell lung cancer

目的评价奥沙利铂加多西紫杉醇与奥沙利铂加长春瑞宾方案治疗晚期非小细胞肺癌的临床疗效和安全性。方法可评价疗效的NSCLC患者以1:1比例随机分为治疗组与对照组。奥沙利铂联合多西紫杉醇组(治疗组)23例,奥沙利铂联合长春瑞宾组(对照组)20例。治疗组为多西紫杉醇75mg/m2,静脉滴注2h,第1天;奥沙利铂(OXA)200mg/m2,静脉滴注2h,第2天。每3周重复一次,行3周期(9周)治疗后判定临床效果。对照组为长春瑞滨25mg/m2静脉推注,第1、8天;奥沙利铂用法同治疗组。结果治疗组总有效率(RR)为56.52%(13/23);对照组总有效率(RR)为55%(11/20)。治疗组和对照组两组患者临床疗效和各项生活质量评分差异无统计学意义(P≥0.05)。治疗组恶心呕吐反应以及血红蛋白下降均较对照组轻。未出现治疗相关性死亡。结论奥沙利铂加多西紫杉醇治疗晚期非小细胞肺癌患者临床疗效高,不良反应轻微。

Objective To compare the effects and safety of oxaliplatin plus docetaxel versus oxaliplatin plus vinorelbine for the treatment for elder patients with advanced non-small cell lung cancer（NSCLC）.Methods The NSCLC patients were selected into Oxaliplatin plus Docetaxel group（therapy group） and Oxaliplatin plus Vinorelbine group（control group） in a rate of 1：1 randomly.23 patients in therapy group,and 20 patients in control group.Therapy group were use Docetaxel 75 mg/m2,iv,2 hours,d1,and Oxaliplatin 200 mg/m2,iv 2 hours d2,and repeated every 3 weeks（one cycle）.The effect was evaluated after three cycles（9 weeks）.The control group were use Vinorelbine 25 mg/m2,iv,2 hours,d1,d8,and Oxaliplatin use as therapy group.Results Overall response rate（ORR） for chemotherapy patients were 56.62%（21/47） in therapy group and 55%（11/20） in control group.There was no statistically difference between the two groups regarding clinical result and quality of life.The nausea and vomitting reation and the decrease of hemoglobin were occurred significantly more frequent in control group.There were no any deaths during treament.Conclusion Oxaliplatin in combination with Docetaxel is effective and relatively well tolerated in chemotherapy elderly patients with advanced non small cell lung cancer.